Calcipotriol Versus Tacrolimus for Mild-to-Moderate Plaque Psoriasis
Calcipotriol and topical tacrolimus have demonstrated similar overall improvements in mild-to-moderate plaque psoriasis after about 12 weeks of treatment. [1] [2]
Calcipotriol showed superior normalization of keratinocyte differentiation markers in one head-to-head mechanistic outcome study. [2]
Tacrolimus had higher rates of application-site burning in one randomized study. [1]
Evidence Base Comparing Efficacy
A randomized open-label, observer-blinded study in adults with mild-to-moderate plaque psoriasis reported no statistically significant differences in change in a local psoriasis severity index at week 12 between tacrolimus gel, tacrolimus cream, and calcipotriol ointment. [1]
A randomized 12-week study measuring both clinical and histologic biomarkers reported comparable reductions in SUM score between calcipotriol ointment and tacrolimus gel and tacrolimus cream. [2]
Treatment Effect Size and Clinical Outcomes
By week 12, median percentage change in the local psoriasis severity index was 55.6% with tacrolimus gel, 50.0% with tacrolimus cream, and 58.6% with calcipotriol ointment, with no statistically significant between-group differences. [1]
Clinical and histologic biomarker changes indicated broadly comparable effects on epidermal proliferation (Ki-67-positive cells) between calcipotriol and tacrolimus preparations. [2]
Medication Selection Algorithm
- Topical vitamin D analogues (calcipotriol) are reasonable noncorticosteroid options for mild-to-moderate plaque psoriasis. [3]
- Topical calcineurin inhibitors (tacrolimus) are reasonable nonsteroidal options in psoriasis patients for which steroid-sparing is desired, including use on sensitive sites. [3]
Monotherapy Versus Combination Therapy
NICE guidance supports combination topical therapy with a potent corticosteroid plus a vitamin D or vitamin D analogue for adults with trunk or limb plaque psoriasis to improve initial clearance compared with monotherapy. [3]
No evidence from the cited head-to-head studies supports combination superiority specifically for calcipotriol versus tacrolimus monotherapy. [1] [2]
Key Evidence Supporting This Recommendation
Tacrolimus versus calcipotriol comparison showed no statistically significant difference in week-12 local severity index change in a randomized study of mild-to-moderate plaque psoriasis. [1]
Calcipotriol demonstrated significantly greater improvement in keratinization/differentiation (K10-positive epidermal surface) compared with tacrolimus preparations in a randomized 12-week biomarker study. [2]
Tacrolimus was associated with more application-site burning than calcipotriol in the randomized study. [1]
Common Pitfalls to Avoid
Interpreting tacrolimus cream results as equivalent across all tacrolimus formulations is a common error because one biomarker study reported more modest effects for tacrolimus cream on certain T-cell subset outcomes compared with tacrolimus gel and calcipotriol. [2]
Expecting rapid steroid-like clearance is a common error because week-to-week clinical improvement in the randomized study increased through the 12-week course rather than appearing as immediate maximal clearance. [1]
Targets or Goals of Therapy
Achieving clear or near-clear skin and maintaining satisfactory control over a multi-week treatment course are standard topical treatment goals used in guideline-directed outcome frameworks. [3]
In clinical trials, response assessment at approximately 8 to 12 weeks has been used to compare topical agents in mild-to-moderate plaque psoriasis. [1] [2]